SBIR Phase II: Software Development for Automatic Scanning and Analysis of Fluorescent Labeled Prostate Cancer Cells

这个小企业创新研究（SBIR）第二阶段项目是双重的。首先，整合第一阶段开发的计算机硬件和软件，自动化复杂的荧光显微镜，允许自动玻片扫描/图像采集和处理，以识别和枚举循环前列腺癌细胞，基于各种荧光标记。将使用正常和癌症患者的血液样本，通过比较自动细胞鉴定（带有细胞识别算法）和人工细胞鉴定，验证自动显微镜的准确性和效率。人类的眼睛。其次，通过标记物获得的数据将与献血者的临床病史（PSA水平、死亡率等）一起输入Cell Works数据库（将在II期完成），以验证数据库。将癌细胞数据与患者PSA水平进行相关性分析。一个潜在的商业应用是，与前列腺癌循环细胞测试一起，协助确定癌症患者的转移。该技术将使Cell Works能够更快、更有效、更准确地进行大量循环细胞测试，并将循环细胞与转移联系起来，并将大大提高CC测试商业化的能力。

This Small Business Innovation Research (SBIR) Phase II project is twofold. First, integrate computer hardware and software, developed in Phase I, to automate a sophisticated fluorescence microscope to allow for automated slide scanning/image acquisition and processing to identify and enumerate circulating prostate cancer cells, based on various fluorescent markers. Blood samples from normal and cancer patients will be used to validate the accuracy and efficiency of the automated microscope by comparing automated cell identification (with a cell recognition algorithm) and manual cell identification ,i.e., the human eye.Second, data obtained with the markers will be entered into the Cell Works database (to be completed in Phase II) along with clinical history of the blood donors ( PSA level, mortality, etc.) for validation of the database. Correlation between cancer cell data and patient PSA level will be made. A potential commercial application is to assist, in conjunction with the Prostate Cancer Circulating Cell Test, in determining metastasis in a cancer patient. The technology will enable Cell Works to more quickly, efficiently, and accurately perform a substantial number of circulating cell tests and correlate circulating cells with metastasis, and will greatly increase the ability to commercialize the CC Test.